HealthEquity stock price target lowered to $109 by RBC Capital

HealthEquity (HQY) delivered a strong fiscal first quarter, with revenue up 15% and adjusted EBITDA up 19%, leading to raised fiscal 2026 guidance and a positive outlook upgrade from Moody's. While this prompted several analyst price target increases and rating affirmations, RBC Capital slightly lowered its target to $109, citing concerns over the impact of lower treasury rates and Federal Reserve rate cut expectations on HQY's HSA cash portfolio yield management. Despite RBC's specific focus on interest rate sensitivity and portfolio strategy, the overall analyst consensus remains a strong buy, projecting significant upside potential.

Analysis

HealthEquity, Inc. (HQY) demonstrated strong fundamental performance in its fiscal first quarter, reporting a 15% year-over-year revenue increase to $330.8 million and a 19% rise in adjusted EBITDA to $140.2 million, surpassing consensus estimates. This growth was driven by a 29% increase in custodial revenue and was significant enough for the company to raise the lower end of its fiscal 2026 revenue guidance and increase its adjusted EBITDA guidance midpoint by $5 million. The positive operational results were further bolstered by an outlook upgrade from Moody's, which moved from stable to positive on its Ba3 corporate family rating, citing improved credit metrics. However, this bullish sentiment is tempered by a specific concern from RBC Capital, which lowered its price target to $109 from $117. RBC's caution stems from the potential impact of lower 5-year treasury rates and anticipated Federal Reserve rate cuts on HealthEquity's earnings. The key variable is how management will handle HSA cash portfolio maturities for fiscal years 2026 and 2027, specifically their strategy regarding forward contracts versus rolling into Enhanced Rates, which will directly influence future yield guidance. Despite RBC's focused concern on interest rate sensitivity, the broader analyst community remains positive, with firms like BTIG, KeyBanc, and Raymond James reaffirming buy-equivalent ratings and Mizuho noting tailwinds from pro-HSA legislation.

Key Decisions for Investors

• Investors should weigh the company's strong Q1 earnings, with 15% revenue growth and raised guidance, against the specific macro risk of lower interest rates impacting future HSA cash yields.
• Closely monitor management's commentary in the upcoming Q2 FY26 results for clarification on their strategy for managing the HSA cash portfolio, as this will be a key determinant of future earnings.
• Consider the company's high valuation, reflected in a P/E ratio of 63, which suggests strong future growth is already priced in, making the stock sensitive to any shifts in the interest rate outlook or operational performance.
• Factor in non-financial catalysts such as favorable pro-HSA legislation and internal progress on reducing fraud-related costs, which could provide upside potential independent of the interest rate environment.